Anaptysbio, Inc. · NASDAQ:ANAB
Anaptysbio — Investor Presentation (September 2022)
24 slides from Anaptysbio's investor presentation, Sep 12, 2022
Slide 1: Corporate Overview September 2022
Corporate Overview September 2022 Nasdaq: ANAB
Slide 2: Forward-looking statements
2 This presentation and any accompanying oral presentation contain “forward‐looking” statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: the timing of the release of data from our clinical trials, inclu
Slide 3: AnaptysBio: Transform Patient Health by Delivering Innovative Immunology Therapeutics
3 AnaptysBio Transform Patient Health by Delivering Innovative Immunology Therapeutics GSK Immuno-Oncology Financial Collaboration • 8-25% royalties and milestones* on JEMPERLI (dostarlimab); Readouts expected in 1L endometrial (2H:22) and 1L ovarian (2H:23) • 4-8% royalties and milestones on additi
Slide 4: Wholly-Owned Antibody Programs in Development
4 All programs generated internally using AnaptysBio’s proprietary antibody platform technology Wholly-Owned Antibody Programs in Development Multiple Clinical-Stage Catalysts Through 2023 Lead Optimization IND - Enabling Phase 1 Phase 3 Generalized Pustular Psoriasis Alopecia Areata Phase 1 Top-Lin
Slide 5: Wholly-Owned Checkpoint Agonists: Rosnilimab and ANB032
Wholly-Owned Checkpoint Agonists: Rosnilimab (Anti-PD-1 Agonist) ANB032 (Anti-BTLA Agonist) Autoimmune and Inflammatory Diseases
Slide 6: Anti-Inflammatory Checkpoint Agonist Antibodies: Novel Therapeutic Class
6 Anti-Inflammatory Checkpoint Agonist Antibodies Novel Therapeutic Class Modulating Immune Cell Function • Our potent anti-inflammatory checkpoint agonists for PD-1 and BTLA modulate function to treat inflammatory disorders by down regulating T-cell mediated immune responses - BTLA is also present
Slide 7: Rosnilimab PD-1 agonist mechanism
7 • PD-1 is a key checkpoint responsible for down-regulating T-cell mediated immune responses - Insufficient PD-1 activity is associated with human inflammatory diseases - Augmenting PD-1 signaling has the potential to suppress T-cell driven human inflammatory diseases • Rosnilimab is an IgG1 antibo
Slide 8: Rosnilimab Phase 1 healthy volunteer results
8 • 144 healthy volunteers enrolled in randomized, double-blind, placebo- controlled SAD and MAD cohorts • Rosnilimab was well tolerated with no dose-limiting toxicities - Most frequent adverse event was mild C- reactive protein increase in 9 (10%) rosnilimab-dosed and 1 (3.3%) severe event in place
Slide 9: Alopecia Areata is an Immune-Mediated Form of Hair Loss
9 Alopecia Areata is an Immune-Mediated Form of Hair Loss Results from Aberrant Inflammation Driven by Activation of Hair Follicle Keratinocyte & Melanocyte Antigen-Specific PD-1+ T cells and IFNɣ Production • PD-1+ T cells infiltrate into hair follicle root sheaths where IL-15 contributes to T cell
Slide 10: Rosnilimab Treatment for Alopecia Areata
10 • Hair follicle infiltrating T cells express high levels of PD-1, leading them to be targeted by rosnilimab, resulting in: - PD-1 agonistic signaling - Inhibition of T cell expansion - Inhibition of T cell IFNɣ secretion - Potential elimination of PD-1 high expressing T cells via IgG1 effector fu
Slide 11: Alopecia Areata Market Overview
11 Alopecia Areata Market Overview A Meaningful Opportunity With Significant Remaining Unmet Patient Need Prevalence and Epidemiology Disease Burden and Unmet Need Limited Treatment Options • Alopecia areata is a chronic condition that affects men, women, and children of all ages • Approximately 1.5
Slide 12: AZURE: Rosnilimab Alopecia Areata Phase 2 Trial
12 AZURE: Rosnilimab Alopecia Areata Phase 2 Trial Top-Line Data Anticipated in Q1 2023 Rosnilimab 400 mg SC q4w n= 45 Ra nd om ize 2 :1 Placebo Treatment Period Follow-Up Period W ee k 0 W ee k 24 W ee k 32 Patient Population • Adult patients with moderate‐to‐severe alopecia areata • At least 50% s
Slide 13: ANB032 BTLA agonist mechanism
13 • BTLA is an inhibitory checkpoint receptor responsible for regulating activation of lymphoid (T and B) cells and myeloid (dendritic) cells - BTLA is also present on myeloid dendritic cells and required for the normal development and maintenance of Tregs • Potentially broadly applicable to autoim
Slide 14: ANB032 Phase 1 healthy volunteer results
14 • 96 healthy volunteers enrolled in randomized, double-blind, placebo-controlled SAD and MAD cohorts - Well-tolerated with no dose limiting toxicities - Most AEs were mild-to-moderate, of short duration, dose independent and resolved without sequelae - No Serious Adverse Events • Favorable PK wit
Slide 15: Wholly-Owned Pipeline: Imsidolimab (Anti-IL-36R) in GPP
Wholly-Owned Pipeline: Imsidolimab (Anti-IL-36R) Generalized Pustular Psoriasis (GPP)
Slide 16: IL-36 Dysfunction Mediates Severe Inflammatory Disease
Normal Individuals IL-36 cytokine signaling balanced by function IL-36 receptor antagonist Disease Patients Uncontrolled signaling due to dysfunctional IL-36 receptor antagonist or elevated IL-36 cytokine levels Treated Patients Anti-IL-36R antibody has the potential to dampen disease by blocking th
Slide 17: Generalized Pustular Psoriasis (GPP): Orphan Disease
17 • GPP is a systemic, life-threatening inflammatory disease characterized by widespread pustules - Patients have a high fever and elevated levels of serum CRP and inflammatory cytokines (e.g., IL-8) - Severe GPP patients can die from cardio-pulmonary failure, exhaustion, toxicity and infection • G
Slide 18: GALLOP: Imsidolimab Phase 2 Trial Design
18 • Moderate‐to‐severe adult generalized pustular psoriasis patients • Baseline mJDA score >6, ≥10% body surface area covered by pustules • No concomitant dermatological condition or infection Patient Population (n=8) • Primary: Improvement in Clinical Global Impression (CGI) based on the modified
Slide 19: GALLOP Phase 2 results
19 • Rapid and sustained efficacy through week 16 – 6 of 8 (75%) patients achieved primary endpoint of improvement in the clinical global impression scale (CGI) at week 4 and week 16 – Early reduction of erythema with skin pustules by week 1 was sustained at 98% reduction relative to baseline at wee
Slide 20: GEMINI Phase 3 trial design
20 Patient Population Ra nd om iza tio n n= 45 * W ee k 0 Key Endpoints • Male and female subjects 18 to 80 years of age • Clinically confirmed diagnosis of GPP as per ERASPEN definition • Baseline Generalized Pustular Psoriasis Physician Global Assessment (GPPPGA) score of at least moderate severit
Slide 21: GSK Immuno-Oncology Financial Collaboration
GSK Immuno-Oncology Financial Collaboration JEMPERLITM (dostarlimab, anti-PD-1 Antagonist) Cobolimab (GSK4069889, anti-TIM-3 Antagonist) GSK4074386 (TSR-033, anti-LAG-3 Antagonist)
Slide 22: JEMPERLI royalties and Sagard monetization
22 JEMPERLI 8% royalty on annual global sales <$1B 12‐25% royalties on global sales ≥ $1B $1.1B in aggregate milestones GSK anticipates ~$1.2‐2.4B peak annual sales for currently approved indications and anticipated 1L endometrial/ovarian approvals** Sagard: JEMPERLI Capped Non‐Recourse Monetization
Slide 23: JEMPERLI and GSK checkpoint clinical programs
Advanced/Recurrent Endometrial 1L Advanced/Recurrent: RUBY (n=740) PD-1 mono or ZEJULA/PD-1 dMMR Pan-Tumor Ovarian 1L Ovarian: FIRST (n=1405) ZEJULA/PD-1 combo OPAL (n=41) ZEJULA/PD-1/Bevacizumab combo NSCLC JASPER (n=53) ZEJULA/PD-1 combo PERLA (n=240): vs. Keytruda in 1L (chemo combo) (Data expect
Slide 24: ‘N y y
4 ‘N N N N . ‘N y y q q y \ wa f ‘ Y | A AnaptysBioW Wf y A |